Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486821 · ClinicalTrials.gov registry record · NA
Ultra-hypofractionated Radiation in Prostate Cancer
A NA study of Early Stage Prostate Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03486821 is a NA study of Early Stage Prostate Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 13 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03486821, a NA study of Early Stage Prostate Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain patient reported outcome.
Conditions Studied
Interventions
- RADIATION Hypofractionated Radiation
Study Locations (1)
Kansas
- University of Kansas Medical Center/ Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486821
The ClinicalTrials.gov registry entry for NCT03486821 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Stage Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Hypofractionated Radiation is the first listed.
NCT03486821 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03486821 about?
NCT03486821 is a clinical study titled "Ultra-hypofractionated Radiation in Prostate Cancer". The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain patient reported outcome.
What is the current status of trial NCT03486821?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2018-03-22. Estimated completion is 2026-03-01.
What conditions does trial NCT03486821 study?
This clinical trial studies the following conditions: Early Stage Prostate Cancer.
What interventions are being tested in trial NCT03486821?
The interventions under investigation include: Hypofractionated Radiation (RADIATION).
Who is sponsoring clinical trial NCT03486821?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03486821 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.